Abstract
Renin–angiotensin–aldosterone system (RAAS) blockade in patients with established heart or kidney disease provides an approximate 20 % relative risk reduction of disease progression, and cardiovascular (CV) or renal end points. There is minimal risk associated with this approach, especially with close monitoring. Whether dual RAAS blockade can provide incremental clinical benefit is of some debate. Overall, there is no CV benefit. However, dual RAAS blockade has not been well tested in patients with renal disease and there is some indication of therapeutic benefit in patients with systolic heart failure.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Messerli FH, Bangalore S, Ram VS (2008) Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 359:426–427
Mann JF, Schmieder RE, McQueen M et al (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553
Bakris GL (2010) Dual RAAS blockade is desirable in kidney disease: con. Kidney Int 78:546–549
Messerli FH (2009) The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 53:468–470
Lattanzio MR, Weir MR (2010) Have we fallen off target with concerns surrounding dual RAAS blockade? Kidney Int 78:539–545
Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30–48
Mehdi UF, Adams-Huet B, Raskin P et al (2009) Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20:2641–2650
Epstein M, Williams GH, Weinberger M et al (2006) Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1:940–951
Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ (2008) Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 51:199–211
Tobe SW, Clase CM, Gao P et al (2011) Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 123:1098–1107
Nakao N, Yoshimura A, Morita H et al (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361:117–124
Kunz R, Wolbers M, Glass T, Mann JF (2008) The COOPERATE trial: a letter of concern. Lancet 371:1575–1576
Fried LF, Duckworth W, Zhang JH et al (2009) Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 4:361–368
Parving HH, Brenner BM, McMurray JJ et al (2009) Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24:1663–1671
Doulton TW, He FJ, MacGregor GA (2005) Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45:880–886
Park S, Bivona BJ, Kobori H et al (2010) Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J Physiol Renal Physiol 298:F37–F48
Vaclavik J, Sedlak R, Plachy M et al (2011) Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 57:1069–1075
McMurray JJ, Ostergren J, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 362:767–771
Hamroff G, Katz SD, Mancini D et al (1999) Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 99:990–992
Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341:709–717
Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321
Parving HH, Persson F, Lewis JB et al (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433–2446
Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF (2009) Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 4:542–551
Krum H, Nolly H, Workman D et al (2002) Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40:117–123
Pitt B, Reichek N, Willenbrock R et al (2003) Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108:1831–1838
Novartis (2011) Novartis announces termination of ALTITUDE study with Rasilez/Tekturna in high-risk patients with diabetes and renal impairment. Ref Type: Generic 20-12-2011 [press release]
Yusuf S, Teo KK, Pogue J et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559
Khosla N, Kalaitzidis R, Bakris GL (2009) Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 30:418–424
Bakris GL, Ruilope L, Locatelli F et al (2007) Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 72:879–885
Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351:543–551
Frimodt-Moller M, Hoj NA, Strandgaard S, Kamper AL (2010) Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease. Nephrol Dial Transplant 25:842–847
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Italia
About this chapter
Cite this chapter
Lattanzio, M.R., Weir, M.R. (2012). Dual Blockade of the Renin–Angiotensin–Aldosterone System: Benefits Versus Adverse Outcomes. In: Berbari, A., Mancia, G. (eds) Special Issues in Hypertension. Springer, Milano. https://doi.org/10.1007/978-88-470-2601-8_34
Download citation
DOI: https://doi.org/10.1007/978-88-470-2601-8_34
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2600-1
Online ISBN: 978-88-470-2601-8
eBook Packages: MedicineMedicine (R0)